Fuji Pharma

Posted on: January 4, 2022 By: Kim Berlowitz With: Comments Off

MTS served as exclusive financial advisor to Fuji Pharma on its acquisition of SULPREP, MINCLEA, FOLIAMIN, and OSVAN in Japan from Nihon Pharma

Comments are closed.

“I have worked with several venture capital and private equity firms over the past 18 years and MTS by far has added the most value and been the most collaborative.”

Peter Vitulli DNA Diagnostics Center

“MTS’s depth of relationships and true expertise in the healthcare sector have exceeded my expectations. It would be hard to imagine a better investor and growth partner for our business”

Seth Segel CEO Woodbury Health Products

“CEA’s experience with MTS was wonderful. They made connections and leveraged relationships whenever possible and in the process accelerated growth and truly strengthened the business. I would jump at the opportunity to work with them again in the future.”

Ulrich Brechbühl CHAMBERLIN EDMONDS

“I have been in the Venture and Private Equity space for a very long time and have created seven companies from start-up to successful exit. I don’t have to tell anyone that I know a good investor when I work with one.”

Cherrill Farnsworth HEALTH HELP

more ceo testimonials*

*The testimonials may not be representative of the experience of other clients, and are not indicative of future performance or success.